GLP-1 Drugs May Cut Psychiatric Admissions

Adults with schizophrenia and Type 2 diabetes who started these drugs had fewer psychiatric hospitalisations in an observational study.

Updated on Nov. 6, 2026 in Diabetes

Plain white injectable pen devices arranged on a pale wooden shelf in soft daylight, with a blurred clinic interior behind them.
A large observational study found adults with schizophrenia and Type 2 diabetes who started GLP-1 receptor agonists had fewer psychiatric hospitalisations over up to two years. AI Illustration. Upload story photo >

A large observational study found that adults with schizophrenia and Type 2 diabetes who started GLP-1 receptor agonists had lower rates of psychiatric hospitalisation over up to two years of follow-up. The findings, published in Lancet Psychiatry in 2026, are relevant to people with both conditions across the United States.

Why it matters

Adults with schizophrenia have elevated rates of Type 2 diabetes and cardiometabolic disease, and psychiatric hospitalisation is a major driver of their care burden. Evidence that a widely used diabetes drug class may be associated with fewer psychiatric admissions could shape conversations about treatment choices in this population.

This observational cohort study followed 70,257 adults with schizophrenia and Type 2 diabetes using electronic health records, with follow-up of up to two years. The hazard ratio of 0.76 for psychiatric hospitalisation compares GLP-1 initiators with non-initiators, though observational designs cannot establish cause.

The players

Lancet Psychiatry

A peer-reviewed journal that publishes research on mental health conditions and their treatment.

US NeuroBlu Data repository

A US electronic health record data resource used for observational research on psychiatric and neurological conditions.

The details

Researchers classified participants by whether they started GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, or none of these treatments between 2018 and 2025. They then compared psychiatric hospitalisation and emergency department outcomes across these groups. The study design can identify associations but cannot by itself explain the biological pathway linking these drugs to fewer admissions.

Timeline

  1. Participants initiated glucose-lowering treatments between 2018 and 2025.

  2. Follow-up for study participants lasted up to two years.

  3. The study was published in Lancet Psychiatry in 2026.

Health Landscape

Adults with schizophrenia have long faced higher rates of Type 2 diabetes and cardiometabolic disease than the general population. This study adds a psychiatric-outcome angle to the existing treatment landscape for this high-need group.

If you or someone you support lives with schizophrenia and Type 2 diabetes, it may be worth asking a prescriber whether a GLP-1 medication is appropriate given overall health needs. Psychiatric hospitalisation and emergency visits are the outcomes examined, so any change in treatment should be discussed with a physician rather than started independently.

The takeaway

Observational evidence links GLP-1 use to fewer psychiatric admissions in this population, but it does not prove cause. Anyone considering a change in diabetes or psychiatric treatment should raise it with their doctor.

Further reading

For broader context on treatment options, explore our Diabetes coverage.